Summary: The aim of this study was to assess the influence of host genetic variations and clinical factors in relation to efavirenz level in HIV-1 infected Thai adults. A total of 100 HIV-infected subjects treated with efavirenz/lamivudine/tenofivir were prospectively enrolled. The panel of CYP2A6, CYP2B6 and CYP3A4/5 polymorphisms was genotyped. At steady state, plasma efavirenz concentrations were measured using high performance liquid chromatography. The relationship between host genetic and clinical factors in terms of efavirenz pharmacokinetics in HIV-1 infected Thai adults was analyzed. The minor allele frequency for CYP2A6 ¹48T>G, CYP2B6 g.18492T>C, CYP3A4*1B c.¹392A>G, CYP3A4*18 c.878T>C and CYP3A5*3 c.6986A>G was 0.14, 0.27, 0.01, 0.03 and 0.38, respectively. Univariant and multivariant analysis indicated associations for CYP2B6 g.18492T>C (p < 0.001 and p = 0.001), aspartate aminotransferase (AST; p = 0.001 and p = 0.006) and blood urea nitrogen (BUN; p = 0.011 and p = 0.016) with plasma efavirenz concentration. However, CYP2A6 ¹48T>G, CYP3A4*1B c.¹392A>G, CYP3A4*18 c.878T>C and CYP3A5*3 c.6986A>G had no significant impact on plasma efavirenz concentration in HIV-1 infected Thai adults. The CYP2B6 g.18492T>C polymorphism, AST and BUN were significantly associated with low efavirenz concentrations. The results from this study can be used to improve the prediction of efavirenz plasma concentration and to optimize its dose in antiretroviral therapy.
Introduction
Efavirenz is metabolized by cytochrome P450 (CYP)2B6, CYP2A6 and CYP3A4/5. 1, 2) However, CYP2B6 is the major metabolizing enzyme involved in the metabolism of efavirenz. [3] [4] [5] The effect of genetic polymorphisms on efavirenz pharmacokinetics attracts much attention because the plasma concentration of efavirenz has been found to be a risk factor for treatment failure and to have the potential for a serious adverse drug reaction (ADR). [6] [7] [8] [9] [10] [11] [12] Many studies have observed an association between CYP2B6 polymorphisms and efavirenz pharmacokinetics. [3] [4] [5] 8) The studies have found an association between CYP2B6*6/*6 (516TT and 785GG) and higher plasma efavirenz concentrations 3) with increased incidence of sleep disorders. [13] [14] [15] [16] Conversely, our previously retrospective study in Thai human immunodeficiency syndrome (HIV)-infected adults showed significant allelic variants (CYP2B6 g.C18492T) which may increase the clearance of efavirenz and thereby decrease efavirenz plasma concentration.
3) At present, treatment failure has been found to be more frequent in patients with a low efavirenz level, compared with those with a high level. [10] [11] [12] As for efavirenz, some investigators have suggested that the lower limit for the therapeutic range of efavirenz should be raised from 1,000-2,300 ng/mL. 17) Therefore, HIV patients who receive treatment with an efavirenzbased regimen and have plasma efavirenz concentration of <1,000 ng/mL seem to have a higher risk for virological failure. [10] [11] [12] 18) Repeated exposure to sub-therapeutic concentrations of efavirenz also increases the chance for the development of resistant viral strains and thus eventual treatment failure.
18) The effect of host genetics on subtherapeutic efavirenz concentration holds considerable interest because the plasma concentration of efavirenz has been found to be a reliable predictor of treatment failure. 19, 20) Clinically, the reasons for inter-individual variability in terms of efavirenz concentrations and efficacy are multifactorial and include differences in gender, metabolism, drug compliance, presence of underlying diseases, and use of concomitant medications as well as genetic factors. 20) Therefore, in the present study we performed a prospective comprehensive investigation to identify the impact of pharmacogenetic and clinical characteristics and potential biochemical factors associated with efavirenz subtherapeutic levels in HIV-1 infected Thai adults receiving a triple therapy regimen of tenofovir (300 mg), lamivudine (300 mg) and efavirenz (600 mg).
Materials and Methods
Subjects: A single-site cohort of HIV-infected patients was prospectively analyzed for this pharmacogenomic study. All subjects provided written informed consent within the cohort study, which included the use of stored samples for future research following specific ethical clearance. Following written informed consent, 100 Thai adults with HIV-1 infection were recruited from the outpatient unit of the Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand. Participants included in this study were all antiretroviral treatment naïve, adult patients who were initiated on the triple therapy regimen of tenofovir (300 mg), lamivudine (300 mg) and efavirenz (600 mg). All enrolled patients were also aged ²18 years and had no opportunistic infections. Patients receiving concomitant treatments that could potentially affect efavirenz pharmacokinetics were excluded. All patients were advised to take the regimen at bedtime. A mid-dose efavirenz plasma concentration was determined at 12 weeks following the initiation of antiretroviral therapy. This study was approved by the Ethics Committee of the Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand.
In all, a total of 100 HIV-1 infections were analyzed for the relationship among plasma efavirenz concentration, genetic polymorphism and clinical factors. In order to minimize other potential factors for CYP2B6 polymorphisms that influence plasma efavirenz level, only the patients who carried CYP2B6 haplotype *1/*1 were analyzed. The CYP2B6 haplotypes, *2 (C64T; rs8192709), *26 (C499G; rs3826711), *6 (G516T; rs3745274), *4 (A785G; rs2279343), *23 (A1375G; rs3211369), *5 (C1459T; rs3211371), and CYP2B6 C21563T (rs8192719) were excluded and only the patients who carried CYP2B6 haplotype *1/*1 were analyzed. All samples were submitted to the Laboratory for Pharmacogenomics and Personalized Medicine, Ramathobidi Hospital, Mahidol University for pharmacogenetic study.
Clinical laboratory data: CD4 cell count by flow cytometry using monoclonal antibodies with three-color reagent (TriTEST, Becton Dickinson BioSciences, Franklin Lakes, NJ) and analyzed with a FACScan flow cytometer (Becton Dickinson BioSciences). Plasma HIV-1 RNA was analyzed by real-time polymerase chain reaction using a COBAS μ AmpliPrep/COBAS μ TaqMan μ HIV-1 test kit (Roche Molecular Systems, Inc., Branchburg, NJ).
Hemoglobin (Hb), blood urea nitrogen (BUN), creatinine, cholesterol, triglyceride, high-density lipoprotein (HDL), low-density lipoprotein (LDL), total bilirubin, direct bilirubin, alkaline phosphatase (ALP), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were also collected.
CYP2A6, CYP2B6 and CYP3A4/5 genotyping: All samples were submitted to the Laboratory for Pharmacogenomics and Personalized Medicine, Ramathibodi Hospital, Mahidol University for pharmacogenetic analysis. Pre-designed TaqMan assays (Applied Biosystems, Foster City, CA), were used to genotype the CYP2A6 ¹48T>G (rs28399433; assay ID C__30634332_10), CYP2B6 g.18492T>C (rs2279345; assay ID C__26823975_10), CYP3A4*1B c.¹392A>G (rs2740574; assay ID AHPAJVY), CYP3A4*18 c.878T>C (rs28371759; assay ID C__27859823_20) and CYP3A5*3 c.6986A>G (rs776746; assay ID C__26201809_30). For SNP analysis, this SNP was genotyped using allele-specific fluorogenic 5A nuclease chain reaction assay with predesigned primers and TaqMan MGB probes (TaqMan SNP Genotyping Assay; Applied Biosystems). Sequence-specific forward and reverse primers to amplify the polymorphic sequence of interest used two TaqMan MGB probes; one probe was labeled with VIC dye and detected the allele 1 sequence, while the second probe was labeled with FAM dye and detected the allele 2 sequence.
Measurement of efavirenz plasma concentrations: The fasting plasma efavirenz level at 12 h after dosing was measured using a validated high performance liquid chromatopraphy assay at 12 weeks of ART inititation (lower limit of quantification: 50 ng/mL). Briefly, patient plasma samples (300 µL) and all calibration and control samples were heat inactivated in a water bath at 56°C for 30 min prior to assay. Sample pretreatment involved protein precipitation with acetonitrile (360 µL), and following centrifugation the sample supernatant was injected into the HPLC machine. Chromatography was performed using an Agilent 1100 HPLC machine with an Omnispher C18 (150 © 4.6 mm I.D./ particle size 5 µm) analytical column (Varian, Palo Alto, CA), a ChromGuard RP guard column and a mobile phase consisting of 10 mM KH 2 PO 4 pH 3.1-acetonitrile (50:50, v/v). The sample peak heights were processed by ChromQuest Software version 4.1. The HPLC assay used in this study was performed in accordance with the protocol developed by the Department of Clinical Pharmacology at the University Medical Centre Nijmegen (Nijmegen, the Netherlands). 21) Statistical analysis: Frequencies (%), mean « standard deviation (S.D.), and median (interquartile range at 25th and 75th, IQR), were used to describe patients' characteristics and laboratory parameters. Genotype distributions were tested for HardyWeinberg equilibrium using » 2 tests. SNPs with a call rate <95% were omitted. A Kruskal-Wallis test was used to determine significant difference in plasma efavirenz concentrations among CYP2A6 ¹48T>G, CYP2B6 g.18492T>C, CYP3A4*1B c.¹392A>G, CYP3A4*18 c.878T>C and CYP3A5*3 c.6986A>G. Mann-Whitney U tests were used to compare plasma efavirenz concentrations between two genotypes. Multivariate and univariate regression analysis was used to describe the relationship between possible confounding factors, i.e. sex, age, weight, height, clinical characteristics, laboratory data and plasma efavirenz concentrations. Stata 12.0 (StataCorp, College Station, TX) and SPSS version 18 (SPSS Inc., Chicago, IL) were used for statistical analysis. Statistical significance was defined as p < 0.05.
Results

Subjects and clinical characteristics:
A total of 100 HIVinfected Thai individuals initiating therapy with an efavirenz-based regimen were recruited in this study. The patient demographics and clinical characters of gender, age, body weight, height and laboratory results are presented in Table 1 . The study population included females (n = 25) and males (n = 75), with an average age («S.D.) of 37 3 and median (IQR) log plasma HIV-1 RNA was 5.78 (5.42-6.32) log copies/mL. Among these patients, lipid profiles and liver and renal function tests were within normal ranges. However, the level of triglyceride, high-density lipoprotein, alkaline phosphatase and aspartate aminotransferase was slightly higher than the reference range.
Allele frequency of CYP2A6, CYP2B6 and CYP3A4/5 polymorphisms: All 100 subjects successfully underwent TaqMan genotyping assay for determining CYP2A6 ¹48T>G, CYP2B6 g.18492T>C, CYP3A4*1B c.¹392A>G, CYP3A4*18 c.878T>C and CYP3A5*3 c.6986A>G which was found to be in HardyWeinberg equilibrium (p > 0.05). The number of patients with each individual genotype is summarized in Table 2 . The minor allele frequency for CYP2A6 ¹48T>G, CYP2B6 g.18492T>C, CYP3A4*1B c.¹392A>G, CYP3A4*18 c.878T>C and CYP3A5*3 c.6986A>G was 0.14, 0.27, 0.01, 0.03 and 0.38, respectively. The analysis of the g.18492T>C genetic polymorphism in the study population revealed that 54% of patients had the wild-type genotype (T/T), 39% had the heterozygous genotype (C/T), and 7% had the polymorphic homozygous genotype (C/C). The minor allele frequency was 0.27. In this study, no patients were identified as having the homozygous variant for CYP3A4*1B c.¹392A>G, CYP3A4*18 c.878T>C.
Correlation between host genetic variations and plasma efavirenz concentration: Overall, the median plasma efavirenz concentration was 2,260 ng/mL (IQR 1,442-3,665) and there was high interindividual variability ranging from 580 ng/mL to 23,350 ng/mL. For CYP2B6 g.18492T>C, the median efavirenz concentrations were as follows: 3,210 ng/mL (IQR 1,900-5,290 ng/mL) for the T/T genotype; 1,900 ng/mL (IQR 1,340-2,290 ng/mL) for the T/C genotype; and 1,200 ng/mL (IQR, 1,070-1,820 ng/mL) for the C/C genotype. In contrast, the efavirenz plasma concentration was slightly higher in subjects with CYP2A6 ¹48T>G heterozygous (T/G; 2,510 ng/mL) and homozygous (G/G; 2,830 ng/mL) variants than in those with wild type (T/T; 2,110 ng/mL), without statistical significance (p = 0.612). In addition, no association was observed between CYP3A4*1B c.¹392A>G, CYP3A4*18 c.878T>C or CYP3A5*3 c.6986A>G and efavirenz plasma concentration (p >0.05). Figure 1 displays the relationship between pharmacogenetic variants and plasma efavirenz levels. Table 3 . 
Discussion
This present prospective study was aimed at determining the effect of host genetic variations and clinical factors in relation to plasma efavirenz concentration in antiretroviral treatment-naïve patients who were initiated on the triple therapy regimen of tenofovir (300 mg), lamivudine (300 mg) and efavirenz (600 mg). Moreover, the frequency of CYP2A6 ¹48T>G, CYP2B6 g.18492T>C, CYP3A4*1B c.¹392A>G, CYP3A4*18 c.878T>C and CYP3A5*3 c.6986A>G was also investigated in this studied population.
Pharmacogenetic analysis for common variant alleles in relevant efavirenz metabolizing genes was performed. With respect to the CYP2A6 ¹48T>G, CYP3A4*1B c.¹392A>G, CYP3A4*18 c.878T>C and CYP3A5*3 c.6986A>G, their influence on efavirenz concentration was not significant. This is consistent with other studies, suggesting that these isoenzymes play a minor role in efavirenz metabolism. [22] [23] [24] However, one recent study did report that being a CYP2A6 variant carrier (*9 or *17) is a significant predictor of high efavirenz concentration. 25) Importantly, the current study shows the predictive value of CYP2B6 g.18492T>C polymorphism for unexpectedly low steady-state plasma efavirenz concentrations in HIV-infected Thai adults. Although the majority of the patients taking efavirenz had a concentration above 1,000 ng/mL, the median efavirenz level for patients with the g.18492 heterozygous variants or homozygous variants was significantly lower than those with the wild-type genotype (p <0.001). The observed trend for low plasma efavirenz level in CYP2B6 g.18492T>C heterozygous (T/C) and homozygous (C/C) variants comparef to homozygous wild type (T/T) carriers is in agreement with our previous study.
3) However, the previously studied population was small, with various antiretroviral regimens. Moreover, the exact timing of the mid-dose pharmacokinetic sample could have varied between subjects from 10 to18 h, which might impact the interpretation of the efavirenz plasma concentration. Therefore, the other possible CYP2B6 genetic polymorphisms that might affect the plasma efavirenz levels could be excluded in this study. We hypothesized that heterozygous and homozygous CYP2B6 g.18492T>C polymorphism may increase CYP2B6 activity and, as a consequence, decrease plasma efavirenz concentration. The finding can be used to identify rapid metabolizers of efavirenz among Thai HIV-1 infected patients. Many studies have reported that treatment failure has been found to be more frequent in patients with a low efavirenz trough level, compared with those with a high level (>1,100 ng/mL). 26, 27) Consequently, this can result in the risk of subtherapeutic efavirenz plasma concentrations and favor the development of viral resistance against efavirenz. 10) Moreover, the present results are in line with a previous report on nevirapine pharmacokinetics. Haplotype analysis of CYP2B6 at 5 loci found that the TGATC haplotype (3003T>C, 516G>T, 785A>G, g.18492T>C and 21563C>T) was significantly associated with nevirapine concentration with increased clearance and lower exposure in Thai HIV infections. 28) Accordingly, the CYP2B6 g.18492T>C variant affects the plasma efavirenz and nevirapine pharmacokinetics, which have been widely used in developing countries as the first-line regimen. 29, 30) Therefore, it is possible that the CYP2B6 g.18492T>C polymorphism may play an important role in determining the risk for development of an efavirenz-and nevirapine-resistant virus.
Significant advances have led to a greater understanding of interactions between genetic and host clinical factors that impact the efficacy of efavirenz. 31) In fact, there are multiple factors that could contribute to affect plasma efavirenz concentration, including gender, age, body weight, liver and renal impairment. 32) Thus, this study was also designed to investigate the various interactions of host genetics with clinical parameters and efavirenz concentration by univariate and multivariate analysis. With respect to the univariate analysis to explain the pharmacological variability, body weight, height, viral load, CYP2B6 g.18492T>C, BUN and AST were all significantly associated with plasma efavirenz concentration. However, the results from the multivariate analysis demonstrated that factors remaining statistically significant with low plasma efavirenz concentration were CYP2B6 g.18492T>C, BUN and AST. In the present study, a clear association was demonstrated between host genetic variations and clinical factors in relation to efavirenz pharmacokinetics in HIV-1 infected Thai adults.
Commonly, antiretroviral regimens with a low genetic barrier to resistance are employed; consequently, the emergence of only 1 or 2 key resistance mutations may confer drug resistance not only to that regimen but also to other agents, thereby limiting subsequent treatment options. Efavirenz has a low genetic barrier to viral resistance, so that a single mutation in the reverse transcriptase gene (e.g., K103N) can confer drug resistance. [33] [34] [35] [36] [37] In Thailand, efavirenz is a preferred component of first-line antiretroviral therapy (ART) for human immunodeficiency virus type 1 (HIV-1) infected individuals. 29, 30) In such a case, the high prevalence of HIV drug resistance in Thai HIV-1 infected patients has been observed. [33] [34] [35] [36] Generally, the development of efavirenz-resistant mutants may be due to repetitive exposure to subtherapeutic drug levels. 36, 37) However, the relationship among host genetic polymorphisms, efavirenz pharmacokinetic exposure and acquisition of HIV drug resistance mutations has not been fully explored. Thus, the association between low efavirenz concentration and efavirenz treatment failure urgently needs to be studied in the Thai HIVinfected population.
